The manufacturers of two high-cost gene therapies for sickle cell disease recently agreed to participate in CMS’s Cell and Gene Therapy Access Model, which could allow the companies to more widely market their treatments and improve access for Medicaid beneficiaries.
Struggling With Adoption, Sickle Cell Gene Therapy Manufacturers Embrace CMS Model
If successful, the new CMS cell and gene therapy access model eventually could expand to oncology or hemophilia products, an Avalere Health expert said.
